Compare Medpace Holdings Inc (MEDP) vs Boston Beer Company Inc (SAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Boston Beer Company Inc — how do they compare? Medpace Holdings Inc trades at $534.38 (market cap $15.08B), while Boston Beer Company Inc trades at $175.5 (market cap $1.88B). The key difference: Medpace Holdings Inc is far larger — about 8× Boston Beer Company Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Boston Beer Company Inc nearer its low. Which is the better fit depends on your goals.
| MEDP | SAM | |
|---|---|---|
Market Cap | $15.08B | $1.88B |
Sector | Technology | Consumer Staples |
52-Week High | $620.59 | $260.05 |
52-Week Low | $308.88 | $161.08 |
Enterprise Value | $14.55B | $1.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Boston Beer Company (SAM) trades at $180.59, up 1.0% with a bullish technical signal from moving averages. The stock shows mixed fundamentals with a P/E of 22.66 and P/S of 0.99, but negative net income margin and ROE. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026. Analyst consensus is mixed with 74% hold ratings and a $204.33 price target, suggesting modest upside potential from current levels.
SAM faces near-term challenges including volume declines and competitive pressures in the hard seltzer segment, offset by strong cash flow generation and innovation in Beyond Beer categories. The company's improved gross margins and cost-saving initiatives provide some stability, but investor sentiment remains cautious ahead of Q2 earnings. The stock presents a balanced risk-reward profile with potential upside to analyst targets but requires monitoring of execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →
